Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting Zura Bio’s scientific disclosures can feel like decoding lab notes written in legalese. Clinical updates buried in an 8-K, cash-runway clues spread across a 10-Q, or executive grants hidden in a proxy statement all shape the future of zb-168—but they’re hard to spot quickly.
Stock Titan’s AI-powered analysis removes that friction. The moment an SEC document hits EDGAR, our platform delivers real-time summaries, plain-language explanations, and red-flag alerts. Need to monitor Zura Bio insider trading Form 4 transactions or catch a fresh capital raise in an S-3? You’ll see it before the market digests the news.
- 10-K & 10-Q: Get the Zura Bio annual report 10-K simplified and each Zura Bio quarterly earnings report 10-Q filing distilled to key R&D spend, trial timelines, and liquidity metrics.
- Form 4: Track Zura Bio Form 4 insider transactions real-time and review detailed Zura Bio executive stock transactions Form 4 history to gauge insider confidence.
- 8-K: Instant alerts with Zura Bio 8-K material events explained—from pivotal Phase data to financing announcements.
- Proxy & Schedules 14A: Understand Zura Bio proxy statement executive compensation without wading through remuneration tables.
Whether you’re understanding Zura Bio SEC documents with AI for due diligence or need a quick Zura Bio earnings report filing analysis, our coverage spans every form type with historical archives and side-by-side comparisons. Zura Bio SEC filings explained simply—so you can focus on assessing clinical milestones, dilution risk, and long-term value, not parsing jargon.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report a collective stake of 4,616,514 Class A Ordinary Shares in ZURA Bio Ltd, representing 7.13% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power for all 4,616,514 shares and no sole voting or dispositive power. The ownership calculation uses a share base of 64,763,950, which combines 61,874,998 outstanding ordinary shares and 2,882,952 pre-funded warrants that the reporting persons could convert subject to a 9.99% maximum exercise limitation. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.
The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.
Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.
The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.
Zura Bio Limited (Nasdaq: ZURA) filed an 8-K announcing a leadership transition in its finance organization. The Board has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren brings more than two decades of biotech experience, most recently serving as CFO/COO of Atara Biotherapeutics and holding multiple senior finance roles at Amgen. His compensation package includes a $475,000 base salary, a target bonus equal to 40 % of salary, and an inducement option for 672,000 Class A shares that vests over four years.
Current CFO Verender Badial tendered his resignation on June 25, 2025. He will stay through the effective date and remain as a non-executive employee until July 31, 2025 to ensure continuity. A Settlement Agreement provides Badial with cash severance and benefits totaling roughly £295,000, accelerated vesting on options covering 186,561 shares, transfer restrictions on those shares for up to three years, and an extension of option exercise periods. Options for 303,100 shares granted on May 8, 2025 will be forfeited.
Key implications for investors:
- The company gains an experienced biotech finance executive with M&A, operations and capital-markets expertise.
- Management states the transition is not related to accounting disagreements, reducing concern over financial reporting integrity.
- Severance and inducement equity create modest near-term cash outflow and long-term dilution, but no immediate impact on operating results.
A press release dated July 1, 2025 regarding these changes was furnished as Exhibit 99.1.
FAQ
What is the current stock price of Zura Bio (ZURA)?
What is the market cap of Zura Bio (ZURA)?
